XBIT XBiotech Inc.

22.79
+0.21  (+1%)
Previous Close 22.58
Open 22.52
Price To Book 14.52
Market Cap 936,365,187
Shares 41,086,669
Volume 898,517
Short Ratio
Av. Daily Volume 657,967
Stock charts supplied by TradingView

NewsSee all news

  1. XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen

    AUSTIN, Texas, Dec. 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today closing of the sale of the Company's True Human antibody Bermekimab to Janssen Biotech, Inc. (Janssen), a Janssen

  2. XBiotech Added to NASDAQ Biotechnology Index

    AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NBI will

  3. XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen

    AUSTIN, Texas, Dec. 07, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that it has entered into a definitive agreement with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson &

  4. XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa

    AUSTIN, Texas, Nov. 19, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announces rapid enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients

  5. XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1⍺ Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema)

    AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL-1a blocking

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

  1. XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen

    AUSTIN, Texas, Dec. 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today closing of the sale of the Company's True Human antibody Bermekimab to Janssen Biotech, Inc. (Janssen), a Janssen

  2. XBiotech Added to NASDAQ Biotechnology Index

    AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NBI will

  3. XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen

    AUSTIN, Texas, Dec. 07, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that it has entered into a definitive agreement with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson &

  4. XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa

    AUSTIN, Texas, Nov. 19, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announces rapid enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients

  5. XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1⍺ Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema)

    AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL-1a blocking

  6. XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa

    AUSTIN, Texas, Oct. 23, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating

  7. XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis

    AUSTIN, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced the first patient was enrolled in a clinical study evaluating bermekimab therapy in adults with systemic sclerosis (SSc), otherwise

  8. XBiotech Announces Oral Presentation of Atopic Dermatitis Results for Bermekimab at 2019 EADV Congress in Madrid, Spain

    AUSTIN, Texas, Sept. 27, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today that Dr. Alice Gottlieb will be presenting clinical findings for bermekimab in the treatment of atopic dermatitis (AD) at the

  9. XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies

    AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in